Banner

Article

FDA considers ban of asthma drugs

The Food and Drug Administration is considering an advisory committee recommendation to ban the use of two drugs for asthma treatment in adults and children.

The Food and Drug Administration is considering an advisory committee recommendation to ban the use of salmeterol and formoterol monotherapy for asthma treatment in adults and children. The committee instead recommends that asthma be treated with products combining the long-acting beta agonists (LABAs) with a steroid.

Although current labeling warns of an increased risk of death while using either LABA alone, committee members told the FDA that too many physicians prescribe them for asthma without a steroid. Used alone, both drugs are also associated with worsened asthma attacks.

While physicians may prescribe a separate steroid along with the LABA, patients often stop using the steroid because the LABA is quick-acting and gives them a type of "rush," says Thomas Casale, MD, executive vice president of the American Academy of Allergy, Asthma and Immunology. Patients don't feel anything with a steroid, since it works over time to reduce inflammation, he says.

Salmeterol and formoterol inhalers are likely to remain on the market because of their efficacy in treating symptoms of chronic obstructive pulmonary disease.

-Heide Aungst, Senior Editor

Related Videos
The new standard for medical malpractice: A conversation with Daniel G. Aaron, M.D., J.D.
The new standard for medical malpractice: What to watch for
The new standard for medical malpractice: A step toward ending defensive medicine?
The new standard for medical malpractice: Can doctors be liable for doing what everyone else does?
The new standard for medical malpractice: What makes a clinical guideline legally defensible?
The new standard for medical malpractice: What it means for day-to-day practice
The new standard for medical malpractice: What changed?
The new standard for medical malpractice: Why the law just changed
ACP policy update 2025: A conversation with Brian E. Outland, PhD
ACP policy update 2025 interview